| P/E (FY) | — | Sales (TTM) | $13.7M |
| Earnings (TTM) | -$114.5M | ROE | −11.48% |
| Net Margin | −1136.25% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | 5.11% |
Janux Therapeutics is a clinical-stage biopharmaceutical company developing cancer immunotherapies built on its TRACTr, TRACIr, and ARM platform technologies. Its candidates include JANX007, a PSMA-targeted TRACTr in Phase 1 for metastatic castration-resistant prostate cancer, and JANX008, an EGFR-targeted candidate in Phase 1 for various solid tumors such as colorectal, head and neck, lung, renal, pancreatic, and triple-negative breast cancers.
| Market Cap | $950.1M | Trading Days | 1283 |
| 52W High | 35.34 |
| 52W Low | 12.12 |
| % Off High | −55.91% |
| YTD | 12.90% | 1Y | −35.70% |
| 3Y | 11.29% | 5Y | −51.96% |
| Since incept. (ann.) | −4.90% |
| Ann. Volatility (1Y) | 74.56% | Ann. Volatility (3Y) | 154.61% |
| Sharpe (1Y) | −0.11 | Sharpe (3Y) | 0.47 |
| Max Drawdown (1Y) | −64.94% | Max Drawdown (3Y) | −81.78% |
| Beta (3Y, vs SPY) | 3.64 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| CBIO | CRESCENT BIOPHARMA, INC. | $968.4M | — |
| MRVI | MARAVAI LIFESCIENCES HOLDINGS, INC. | $974.4M | — |
| JBIO | Jade Biosciences, Inc. | $987.2M | — |
| OPK | OPKO HEALTH, INC. | $996.3M | — |
| AMPH | Amphastar Pharmaceuticals, Inc. | $898.6M | 10.0 |
| ANRO | Alto Neuroscience, Inc. | $1.00B | — |
| AVTX | Avalo Therapeutics, Inc. | $1.02B | — |
| CMMB | Chemomab Therapeutics Ltd. | $880.3M | — |
| OLMA | Olema Pharmaceuticals, Inc. | $1.03B | — |
| ABUS | Arbutus Biopharma Corp | $871.1M | — |
| TBPH | Theravance Biopharma, Inc. |
| $868.7M |
| 8.2 |
| LXRX | LEXICON PHARMACEUTICALS, INC. | $1.04B | — |